107 related articles for article (PubMed ID: 23199953)
1. New technologies and procedures for cervical cancer screening.
Cuzick J; Bergeron C; von Knebel Doeberitz M; Gravitt P; Jeronimo J; Lorincz AT; J L M Meijer C; Sankaranarayanan R; J F Snijders P; Szarewski A
Vaccine; 2012 Nov; 30 Suppl 5():F107-16. PubMed ID: 23199953
[TBL] [Abstract][Full Text] [Related]
2. Introduction of human papillomavirus DNA screening in the world: 15 years of experience.
Castle PE; de Sanjosé S; Qiao YL; Belinson JL; Lazcano-Ponce E; Kinney W
Vaccine; 2012 Nov; 30 Suppl 5():F117-22. PubMed ID: 23199954
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
[TBL] [Abstract][Full Text] [Related]
4. Chapter 10: New dimensions in cervical cancer screening.
Cuzick J; Mayrand MH; Ronco G; Snijders P; Wardle J
Vaccine; 2006 Aug; 24 Suppl 3():S3/90-7. PubMed ID: 16950022
[TBL] [Abstract][Full Text] [Related]
5. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience.
Lonky NM; Mahdavi A; Wolde-Tsadik G; Bajamundi K; Felix JC
J Low Genit Tract Dis; 2010 Jul; 14(3):200-5. PubMed ID: 20592555
[TBL] [Abstract][Full Text] [Related]
7. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
[TBL] [Abstract][Full Text] [Related]
8. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus testing for primary cervical cancer screening.
Grce M; Davies P
Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
[TBL] [Abstract][Full Text] [Related]
10. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection.
Harvey M; Stout S; Starkey CR; Hendren R; Holt S; Miller GC
J Clin Virol; 2009 Jul; 45 Suppl 1():S79-83. PubMed ID: 19651373
[TBL] [Abstract][Full Text] [Related]
11. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma.
Lie AK; Kristensen G
Expert Rev Mol Diagn; 2008 Jul; 8(4):405-15. PubMed ID: 18598223
[TBL] [Abstract][Full Text] [Related]
13. High performance of a new PCR-based urine assay for HPV-DNA detection and genotyping.
Tanzi E; Bianchi S; Fasolo MM; Frati ER; Mazza F; Martinelli M; Colzani D; Beretta R; Zappa A; Orlando G
J Med Virol; 2013 Jan; 85(1):91-8. PubMed ID: 23097252
[TBL] [Abstract][Full Text] [Related]
14. A comparative review of laboratory-developed tests utilizing Invader HPV analyte-specific reagents for the detection of high-risk human papillomavirus.
Stillman MJ; Day SP; Schutzbank TE
J Clin Virol; 2009 Jul; 45 Suppl 1():S73-7. PubMed ID: 19651372
[TBL] [Abstract][Full Text] [Related]
15. High-risk HPV DNA testing and HPV-16/18 genotyping: what is the clinical application?
Twiggs LB; Hopkins M
J Low Genit Tract Dis; 2011 Jul; 15(3):224-30. PubMed ID: 21716051
[TBL] [Abstract][Full Text] [Related]
16. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
[TBL] [Abstract][Full Text] [Related]
17. Nucleic acid tests for the detection of alpha human papillomaviruses.
Poljak M; Cuzick J; Kocjan BJ; Iftner T; Dillner J; Arbyn M
Vaccine; 2012 Nov; 30 Suppl 5():F100-6. PubMed ID: 23199952
[TBL] [Abstract][Full Text] [Related]
18. Overview of cervical cancer screening practices in the extended Middle East and North Africa countries.
Sancho-Garnier H; Khazraji YC; Cherif MH; Mahnane A; Hsairi M; El Shalakamy A; Osgul N; Tuncer M; Jumaan AO; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G51-7. PubMed ID: 24331820
[TBL] [Abstract][Full Text] [Related]
19. Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening.
Hesselink AT; Meijer CJ; Poljak M; Berkhof J; van Kemenade FJ; van der Salm ML; Bogaarts M; Snijders PJ; Heideman DA
J Clin Microbiol; 2013 Jul; 51(7):2409-10. PubMed ID: 23637297
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus (HPV) screening and cervical cancer burden. A Brazilian perspective.
Lorenzi AT; Syrjänen KJ; Longatto-Filho A
Virol J; 2015 Jul; 12():112. PubMed ID: 26208521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
